Form 4 for NKTR NEKTAR THERAPEUTICS
Accepted 2024-12-17 00:00:00 ET · period of report 2024-12-13 · accession 0000950170-24-137543 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-17 | 2024-12-13 | NKTR | ROBIN HOWARD W | Pres, CEO, Dir | A - Grant | $0.00 | +410.6K | 1.24M | +49% | $0 |
| DM | 2024-12-17 | 2024-12-13 | NKTR | ROBIN HOWARD W | Pres, CEO, Dir | A - Grant | $0.00 | +2.12M | 821.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-13 | A | A | 410,625 | $0.00 | 1,242,705 | D | — | — | (F1) Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on August 15, 2022 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. (F2) The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 18, 2024 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on December 13, 2024 (subject to remaining time-based vesting requirements). |
| 2 | Derivative | Stock Option | 2024-12-13 | A | A | 1,300,000 | $0.00 | 1,300,000 | D | $1.01 · — to 2032-12-12 | 1,300,000 Common Stock | (F5) Stock options vest over four years from the date of grant, (December 13, 2024) in equal monthly installments based on continued service. |
| 3 | Derivative | Stock Option | 2024-12-13 | A | A | 821,250 | $0.00 | 821,250 | D | $4.91 · — to 2030-08-14 | 821,250 Common Stock | (F3) These stock options were granted on August 15, 2022 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant. (F4) The Compensation Committee determined on November 18, 2024 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on December 13, 2024 (subject to remaining time-based vesting requirements). |